Global Benign Prostatic Hyperplasia Therapeutics Market Research Report 2026(Status And Outlook)

Buy Now
Share to
Facebook
Twitter
LinkedIn
WhatsApp
Base Year
2026
Forecast Period
2024-2029
Pages
147
Industry
Medical Devices
Regions
Global
Updated
February 2026

Report Overview


Report Overview
Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the diseaseThe global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The global Benign Prostatic Hyperplasia Therapeutics market size was estimated at USD 7116.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 3.40% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Benign Prostatic Hyperplasia Therapeutics market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Benign Prostatic Hyperplasia Therapeutics market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Benign Prostatic Hyperplasia Therapeutics market.
Global Benign Prostatic Hyperplasia Therapeutics Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH and Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck and Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited

Market Segmentation (by Type)
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others

Market Segmentation (by Application)
Mono Drug Therapy
Combination Drug Therapy

Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Benign Prostatic Hyperplasia Therapeutics Market
Overview of the regional outlook of the Benign Prostatic Hyperplasia Therapeutics Market:

Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Benign Prostatic Hyperplasia Therapeutics Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the markets competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porters five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Benign Prostatic Hyperplasia Therapeutics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.



Table of Contents

  • 1 Research Methodology and Statistical Scope
    • 1.1 Market Definition and Statistical Scope of Benign Prostatic Hyperplasia Therapeutics
    • 1.2 Key Market Segments
      • 1.2.1 Benign Prostatic Hyperplasia Therapeutics Segment by Type
      • 1.2.2 Benign Prostatic Hyperplasia Therapeutics Segment by Application
    • 1.3 Methodology & Sources of Information
      • 1.3.1 Research Methodology
      • 1.3.2 Research Process
      • 1.3.3 Market Breakdown and Data Triangulation
      • 1.3.4 Base Year
      • 1.3.5 Report Assumptions & Caveats
  • 2 Benign Prostatic Hyperplasia Therapeutics Market Overview
    • 2.1 Global Market Overview
      • 2.1.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size (M USD) Estimates and Forecasts (2020-2035)
      • 2.1.2 Global Benign Prostatic Hyperplasia Therapeutics Sales Estimates and Forecasts (2020-2035)
    • 2.2 Market Segment Executive Summary
    • 2.3 Global Market Size by Region
  • 3 Benign Prostatic Hyperplasia Therapeutics Market Competitive Landscape
    • 3.1 Company Assessment Quadrant
    • 3.2 Global Benign Prostatic Hyperplasia Therapeutics Product Life Cycle
    • 3.3 Global Benign Prostatic Hyperplasia Therapeutics Sales by Manufacturers (2020-2025)
    • 3.4 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Manufacturers (2020-2025)
    • 3.5 Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.6 Global Benign Prostatic Hyperplasia Therapeutics Average Price by Manufacturers (2020-2025)
    • 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
    • 3.8 Benign Prostatic Hyperplasia Therapeutics Market Competitive Situation and Trends
      • 3.8.1 Benign Prostatic Hyperplasia Therapeutics Market Concentration Rate
      • 3.8.2 Global 5 and 10 Largest Benign Prostatic Hyperplasia Therapeutics Players Market Share by Revenue
      • 3.8.3 Mergers & Acquisitions, Expansion
  • 4 Benign Prostatic Hyperplasia Therapeutics Industry Chain Analysis
    • 4.1 Benign Prostatic Hyperplasia Therapeutics Industry Chain Analysis
    • 4.2 Market Overview of Key Raw Materials
    • 4.3 Midstream Market Analysis
    • 4.4 Downstream Customer Analysis
  • 5 The Development and Dynamics of Benign Prostatic Hyperplasia Therapeutics Market
    • 5.1 Key Development Trends
    • 5.2 Driving Factors
    • 5.3 Market Challenges
    • 5.4 Industry News
      • 5.4.1 New Product Developments
      • 5.4.2 Mergers & Acquisitions
      • 5.4.3 Expansions
      • 5.4.4 Collaboration/Supply Contracts
    • 5.5 PEST Analysis
      • 5.5.1 Industry Policies Analysis
      • 5.5.2 Economic Environment Analysis
      • 5.5.3 Social Environment Analysis
      • 5.5.4 Technological Environment Analysis
    • 5.6 Global Benign Prostatic Hyperplasia Therapeutics Market Porters Five Forces Analysis
      • 5.6.1 Global Trade Frictions
      • 5.6.2 U.S. Tariff Policy – April 2025
      • 5.6.3 Global Trade Frictions and Their Impacts to Benign Prostatic Hyperplasia Therapeutics Market
    • 5.7 ESG Ratings of Leading Companies
  • 6 Benign Prostatic Hyperplasia Therapeutics Market Segmentation by Type
    • 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
    • 6.2 Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2020-2025)
    • 6.3 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2020-2025)
    • 6.4 Global Benign Prostatic Hyperplasia Therapeutics Price by Type (2020-2025)
  • 7 Benign Prostatic Hyperplasia Therapeutics Market Segmentation by Application
    • 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
    • 7.2 Global Benign Prostatic Hyperplasia Therapeutics Market Sales by Application (2020-2025)
    • 7.3 Global Benign Prostatic Hyperplasia Therapeutics Market Size (M USD) by Application (2020-2025)
    • 7.4 Global Benign Prostatic Hyperplasia Therapeutics Sales Growth Rate by Application (2020-2025)
  • 8 Benign Prostatic Hyperplasia Therapeutics Market Sales by Region
    • 8.1 Global Benign Prostatic Hyperplasia Therapeutics Sales by Region
      • 8.1.1 Global Benign Prostatic Hyperplasia Therapeutics Sales by Region
      • 8.1.2 Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Region
    • 8.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region
      • 8.2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region
      • 8.2.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region
    • 8.3 North America
      • 8.3.1 North America Benign Prostatic Hyperplasia Therapeutics Sales by Country
      • 8.3.2 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country
      • 8.3.3 U.S. Market Overview
      • 8.3.4 Canada Market Overview
      • 8.3.5 Mexico Market Overview
    • 8.4 Europe
      • 8.4.1 Europe Benign Prostatic Hyperplasia Therapeutics Sales by Country
      • 8.4.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country
      • 8.4.3 Germany Market Overview
      • 8.4.4 France Market Overview
      • 8.4.5 U.K. Market Overview
      • 8.4.6 Italy Market Overview
      • 8.4.7 Spain Market Overview
    • 8.5 Asia Pacific
      • 8.5.1 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Sales by Region
      • 8.5.2 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region
      • 8.5.3 China Market Overview
      • 8.5.4 Japan Market Overview
      • 8.5.5 South Korea Market Overview
      • 8.5.6 India Market Overview
      • 8.5.7 Southeast Asia Market Overview
    • 8.6 South America
      • 8.6.1 South America Benign Prostatic Hyperplasia Therapeutics Sales by Country
      • 8.6.2 South America Benign Prostatic Hyperplasia Therapeutics Market Size by Country
      • 8.6.3 Brazil Market Overview
      • 8.6.4 Argentina Market Overview
      • 8.6.5 Columbia Market Overview
    • 8.7 Middle East and Africa
      • 8.7.1 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales by Region
      • 8.7.2 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Region
      • 8.7.3 Saudi Arabia Market Overview
      • 8.7.4 UAE Market Overview
      • 8.7.5 Egypt Market Overview
      • 8.7.6 Nigeria Market Overview
      • 8.7.7 South Africa Market Overview
  • 9 Benign Prostatic Hyperplasia Therapeutics Market Production by Region
    • 9.1 Global Production of Benign Prostatic Hyperplasia Therapeutics by Region(2020-2025)
    • 9.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Region (2020-2025)
    • 9.3 Global Benign Prostatic Hyperplasia Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
    • 9.4 North America Benign Prostatic Hyperplasia Therapeutics Production
      • 9.4.1 North America Benign Prostatic Hyperplasia Therapeutics Production Growth Rate (2020-2025)
      • 9.4.2 North America Benign Prostatic Hyperplasia Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
    • 9.5 Europe Benign Prostatic Hyperplasia Therapeutics Production
      • 9.5.1 Europe Benign Prostatic Hyperplasia Therapeutics Production Growth Rate (2020-2025)
      • 9.5.2 Europe Benign Prostatic Hyperplasia Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
    • 9.6 Japan Benign Prostatic Hyperplasia Therapeutics Production (2020-2025)
      • 9.6.1 Japan Benign Prostatic Hyperplasia Therapeutics Production Growth Rate (2020-2025)
      • 9.6.2 Japan Benign Prostatic Hyperplasia Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
    • 9.7 China Benign Prostatic Hyperplasia Therapeutics Production (2020-2025)
      • 9.7.1 China Benign Prostatic Hyperplasia Therapeutics Production Growth Rate (2020-2025)
      • 9.7.2 China Benign Prostatic Hyperplasia Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
  • 10 Key Companies Profile
    • 10.1 Abbott Laboratories
      • 10.1.1 Abbott Laboratories Basic Information
      • 10.1.2 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.1.4 Abbott Laboratories Business Overview
      • 10.1.5 Abbott Laboratories SWOT Analysis
      • 10.1.6 Abbott Laboratories Recent Developments
    • 10.2 Allergan plc
      • 10.2.1 Allergan plc Basic Information
      • 10.2.2 Allergan plc Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.2.4 Allergan plc Business Overview
      • 10.2.5 Allergan plc SWOT Analysis
      • 10.2.6 Allergan plc Recent Developments
    • 10.3 Astellas Pharma
      • 10.3.1 Astellas Pharma Basic Information
      • 10.3.2 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.3.4 Astellas Pharma Business Overview
      • 10.3.5 Astellas Pharma SWOT Analysis
      • 10.3.6 Astellas Pharma Recent Developments
    • 10.4 Boehringer Ingelheim Pharma GmbH and Co. KG
      • 10.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Basic Information
      • 10.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
      • 10.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments
    • 10.5 Eli Lilly and Company
      • 10.5.1 Eli Lilly and Company Basic Information
      • 10.5.2 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.5.4 Eli Lilly and Company Business Overview
      • 10.5.5 Eli Lilly and Company Recent Developments
    • 10.6 GlaxoSmithKline plc
      • 10.6.1 GlaxoSmithKline plc Basic Information
      • 10.6.2 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.6.4 GlaxoSmithKline plc Business Overview
      • 10.6.5 GlaxoSmithKline plc Recent Developments
    • 10.7 Merck and Co.
      • 10.7.1 Merck and Co. Basic Information
      • 10.7.2 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.7.4 Merck and Co. Business Overview
      • 10.7.5 Merck and Co. Recent Developments
    • 10.8 Pfizer
      • 10.8.1 Pfizer Basic Information
      • 10.8.2 Pfizer Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.8.4 Pfizer Business Overview
      • 10.8.5 Pfizer Recent Developments
    • 10.9 Sanofi
      • 10.9.1 Sanofi Basic Information
      • 10.9.2 Sanofi Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.9.4 Sanofi Business Overview
      • 10.9.5 Sanofi Recent Developments
    • 10.10 Teva Pharmaceutical Industries Limited
      • 10.10.1 Teva Pharmaceutical Industries Limited Basic Information
      • 10.10.2 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product Overview
      • 10.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product Market Performance
      • 10.10.4 Teva Pharmaceutical Industries Limited Business Overview
      • 10.10.5 Teva Pharmaceutical Industries Limited Recent Developments
  • 11 Benign Prostatic Hyperplasia Therapeutics Market Forecast by Region
    • 11.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast
    • 11.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Region
      • 11.2.1 North America Market Size Forecast by Country
      • 11.2.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Country
      • 11.2.3 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Region
      • 11.2.4 South America Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Country
      • 11.2.5 Middle East and Africa Forecasted Sales of Benign Prostatic Hyperplasia Therapeutics by Country
  • 12 Forecast Market by Type and by Application (2026-2035)
    • 12.1 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Type (2026-2035)
      • 12.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia Therapeutics by Type (2026-2035)
      • 12.1.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Type (2026-2035)
      • 12.1.3 Global Forecasted Price of Benign Prostatic Hyperplasia Therapeutics by Type (2026-2035)
    • 12.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Application (2026-2035)
      • 12.2.1 Global Benign Prostatic Hyperplasia Therapeutics Sales (K Units) Forecast by Application
      • 12.2.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size (M USD) Forecast by Application (2026-2035)
  • 13 Conclusion and Key Findings

Frequently Asked Questions

JSB Market Research is a global provider of market research reports, industry insights, and business intelligence solutions. We help companies, analysts, and decision-makers gain a deeper understanding of global and regional markets.

Our reports deliver data-driven insights, market opportunities, competitive landscapes, and future forecasts. These help your business make informed decisions, enter new markets confidently, and stay ahead of industry trends.

Yes. We offer tailored research services designed to meet your specific market, product, or competitor analysis needs. Our experts work closely with clients to deliver precise, relevant, and actionable insights.

Browse the desired report, select your preferred license type, and complete payment through our secure checkout. For corporate purchases or invoice payments, you can contact our support team directly.

Yes. You can request sample pages or a report overview. This helps you understand the structure, methodology, and depth of analysis before purchasing.